Responses
Clinical and epidemiological research
Extended report
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
Compose a Response to This Article
Other responses
No responses have been published for this article.